Home>

Products

Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Continue shopping Get Notified

Anti-CD154 [5C8H1]

Anti-CD154 [5C8H1]
Product Type: Therapeutics (In Vivo)
Format: Anti-CD154, 5C8, mouse variable region, human IgG1 Fc
Clone ID: 5C8H1
RRID: AB_2716324
Common Names: Anti-CD154 [5C8H1] | Human/mouse chimeric anti-CD154 | aCD154_5C8_mumu_G1k_hosa | PR-1547 | NHP17 | CLD32 | NHP00093 | CAT-00145
Target: CD154_CD40LG
Reactivity: Human (Homo sapiens) Rhesus Macaque (Macaca mulatta) Cynomolgus Monkey (Macaca fascicularis) Olive Baboon (Papio anubis)
Applications: in vivo
Description:

5C8H1: Human recombinant (mouse/human chimeric) anti-CD154 antibody. V-regions from mouse 5C8 clone; C-regions human IgG1-kappa.
Modifications: None
Restrictions: No
Sponsor: NIAID
How to cite (Methods): The Anti-CD154 [5C8H1] antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat#PR-1547,RRID:AB_2716324).
How to cite (Acknowledgments): The Anti-CD154 [5C8H1] antibody used in this study was provided by the NIH Nonhuman Primate Reagent Resource (NIAID U24 AI126683).

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.

CAN'T FIND EXACTLY WHAT YOUR RESEARCH REQUIRES?

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2024